Prostrakan Share Discussion Threads

[brucie5] 21/7/2010 16:49

Chaps, you may well be right. But bear in mind that this is a company on the cusp of turning a profit, at a share price slightly less than half its peak, where there has been some decent, though not overwhelming director buying just above where we are now. Sales seem to be increasing, and there doesn't seem to be anything fundamentally wrong with the business model, even if sales of Sancuso were relatively disappointing. I struggle to find a negative analyst's report, and quite a lot of coverage has been far more positive than you at substantially higher levels.

I'd like to think that the chart is beginning to anticipate better news than you in August, though I agree that volume is thin. You undoubtedly know more than I. But then I have only just bought in.

[grimraider] 21/7/2010 16:15

Craigends

What do you reckon the likelyhood of succes? Been sitting on these some time, considering cutting losses

[craigends] 21/7/2010 16:07

Grimraider
I agree - increasing market share and clearance through process is needed to move this.

[grimraider] 21/7/2010 15:29

Craigends

Difficult to see what the attraction of a purchase of PSK would be - no clear product benefits in todays market, only hope is that they correct their poor US market penetration to achieve good profitability - despite highly remunerated senior management!

[craigends] 21/7/2010 13:45

Brucie
the trading volumes are so low are they really meaningful - most PI's who've ridden this roller coaster looking for good harvest in August report. With MA's arising (see SSL) personally keep wondering if there is opportunity for PSK being absorbed?

[grimraider] 21/7/2010 13:43

You are brave Brucie5. I feel stock is currently over valued as US results for Sancuso are I suspect below expectations, Abstral has strong competition in Europe and potentially once licensed in US = potentially limited earner, Testosterone gel delayed in US. None of the products are fantastic or high potential in the current cost cutting healthcare environment - I am holding back on this one

[brucie5] 21/7/2010 09:57

Remarkably quiet here given the promising lift off 70p. Can't see any buying yet, though, so not sure what's going on behind the scenes. 80p seems to be a natural first target on any renewal of interest in the shares. For the time being, the share price seesm to have found good support. About time too.

[grimraider] 25/6/2010 10:11

Hi Zulu

Any good news to pull share price up?

[grimraider] 07/5/2010 14:16

Still going south at an alarming rate, doesnt look like much joy on the US Sales either

[farmsted] 07/5/2010 11:40

Pleasing to see the Direcotors are buying.

[jdung] 05/5/2010 08:13

81p looking support at now.
any news?

[grimraider] 29/4/2010 10:41

Farmsted - on their limited salaries they cant afford to buy even at this level! Only bright spot is that major competitor product has been delayed by FDA - AP Pharma

[farmsted] 28/4/2010 16:34

After a month in free fall we should soon be seeing the present directors buying so that the merry go round can start all over again. I hope then I can jump ship!

[zulu002] 31/3/2010 14:45

ProStrakan Group plc

31 March 2010


ProStrakan Group plc Share Plans


ProStrakan Group plc ("the Company") announces that on 26 March 2010 it made a
grant of awards and options over the Company's ordinary shares of 5 pence each
under the Performance Share Plan ("PSP") to Executive Directors and Persons
Discharging Managerial Responsibilities ("PDMR") as detailed in the table below.


+-----------+-----------+---------+-----------+
| Name | Role | No of | Total |
| | | shares | No. of |
| | | subject | options |
| | | to | and |
| | | awards | awards |
| | | | now |
| | | | held |
+-----------+-----------+---------+-----------+
| Wilson | Executive | 340,000 | 4,930,964 |
| Totten | Director | | |
+-----------+-----------+---------+-----------+
| Allan | Executive | 185,000 | 948,027 |
| Watson | Director | | |
+-----------+-----------+---------+-----------+
| Nigel | PDMR | 162,000 | 1,086,170 |
| Atherton | | | |
+-----------+-----------+---------+-----------+
| Andrew | PDMR | 156,000 | 1,436,976 |
| McLean | | | |
+-----------+-----------+---------+-----------+
| Abid | PDMR | 200,000 | 1,413,193 |
| Karim | | | |
+-----------+-----------+---------+-----------+
| Tom | PDMR | 155,000 | 1,274,393 |
| Stratford | | | |
+-----------+-----------+---------+-----------+
| Beth | PDMR | 92,000 | 405,762 |
| Tope | | | |
+-----------+-----------+---------+-----------+


Awards granted under the PSP will vest on 26 March 2013 but only to the extent
that certain performance criteria are satisfied by the Company over a three year
performance period that commenced on 26 March 2010. No consideration is payable
for the grant of the Awards and the receipt of ordinary 5p shares is conditional
upon meeting the performance criteria. It is currently intended that the
Company's Employee Benefit Trust will acquire new shares to fulfill any
obligation arising from the vesting of the Awards by 26 March 2013.

The notification of these Awards is intended to satisfy the Company's
obligations under Disclosure and Transparency Rule 3.1.4.

[the_doctor] 29/3/2010 17:05

'the old directors knew when to bail out'

yep!

[farmsted] 29/3/2010 16:52

Tha Bigger Picture seems to have disappeared and the shares are in free fall, the old directors knew when to bail out.

[farmsted] 29/3/2010 16:51

Tha Bigger Picture seems to have disappeared and the shares are in free fall, the old directors knew when to bail out.

[jdung] 26/3/2010 10:11

now share price 95p, maybe "buy" at this price ?
trade line support at 95-105p. ??

[zulu002] 17/3/2010 09:13

Citywire
16/03/2010

Numis : buy and 240p target for ProStrakan.

[zulu002] 12/3/2010 10:21

Citywire 11/03/10

Charles Stanley upgrades ProStrakan to buy from add with a 127p target.

[zulu002] 12/3/2010 10:16

Scotsman 10/03/10

ProStrakan

98p unchanged

Broker says BUY

AHEAD of results next week from the drugs developer, analysts at KBC Peel Hunt have upgraded ProStrakan, noting "the shares have fallen too far". The broker said of its products: "We consider the setbacks for Sancuso are now fully priced in and the market is ignoring the potential upside from Abstral and Cellegesic."

[the_doctor] 20/1/2010 15:45

Craig

It has massive debt, its products arent hugely innovative and enter challenging markets.
When the current batch of products mature (they will do quickly), it is unclear what they'll follow up with.

At this price, it is no bargain!